Cost-effectiveness analysis of anidulafungin versus fluconazole for the treatment of invasive candidiasis

Chin Neoh, Danny Liew, Monica Slavin, Debbie Marriott, Sharon Chen, Orla Morrissey, Kay Stewart, David Kong

Research output: Contribution to journalArticleResearchpeer-review

24 Citations (Scopus)


Anidulafungin was found to be non-inferior to and possibly more efficacious than fluconazole for treatment of invasive candidiasis (IC) in a major randomized clinical trial (RCT). There are no data comparing the cost-effectiveness between azoles and echinocandins in treating IC. This economic analysis investigated the cost-effectiveness of anidulafungin compared with fluconazole for treatment of IC in an Australian setting.
Original languageEnglish
Pages (from-to)1906-1915
Number of pages10
JournalJournal of Antimicrobial Chemotherapy
Publication statusPublished - 2011

Cite this